TY - JOUR
T1 - Hypoxia promotes synergy between mitomycin c and bortezomib through a coordinated process of Bcl-xL phosphorylation and mitochondrial translocation of p53
AU - Song, Xinxin
AU - Dilly, Ashok Kumar
AU - Choudry, Haroon Asif
AU - Bartlett, David L.
AU - Kwon, Yong Tae
AU - Lee, Yong J.
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/12
Y1 - 2015/12
N2 - Colorectal peritoneal carcinomatosis (CPC) exhibits severe tumor hypoxia, leading to drug resistance and disease aggressiveness. This study demonstrates that the combination of the chemotherapeutic agent mitomycin C with the proteasome inhibitor bortezomib induced synergistic cytotoxicity and apoptosis, which was even more effective under hypoxia in colorectal cancer cells. The combination of mitomycin C and bortezomib at sublethal doses induced activation of c-Jun NH2-Terminal kinase and p38 mitogen-Activated protein kinase and resulted in Bcl-xL phosphorylation at Serine 62, leading to dissociation of Bcl-xL from proapoptotic Bak. Interestingly, the intracellular level of p53 became elevated and p53 translocated to the mitochondria during the combinatorial treatment, in particular under hypoxia. The coordinated action of Bcl-xL phosphorylation and p53 translocation to the mitochondria resulted in conformational activation of Bak oligomerization, facilitating cytochrome c release and apoptosis induction. In addition, the combinatorial treatment with mitomycin C and bortezomib significantly inhibited intraperitoneal tumor growth in LS174T cells and increased apoptosis, especially under hypoxic conditions in vivo. This study provides a preclinical rationale for the use of combination therapies for CPC patients. Implications: The combination of a chemotherapy agent and proteasome inhibitor at sublethal doses induced synergistic apoptosis, in particular under hypoxia, in vitro and in vivo through coordinated action of Bcl-xL and p53 on Bak activation.
AB - Colorectal peritoneal carcinomatosis (CPC) exhibits severe tumor hypoxia, leading to drug resistance and disease aggressiveness. This study demonstrates that the combination of the chemotherapeutic agent mitomycin C with the proteasome inhibitor bortezomib induced synergistic cytotoxicity and apoptosis, which was even more effective under hypoxia in colorectal cancer cells. The combination of mitomycin C and bortezomib at sublethal doses induced activation of c-Jun NH2-Terminal kinase and p38 mitogen-Activated protein kinase and resulted in Bcl-xL phosphorylation at Serine 62, leading to dissociation of Bcl-xL from proapoptotic Bak. Interestingly, the intracellular level of p53 became elevated and p53 translocated to the mitochondria during the combinatorial treatment, in particular under hypoxia. The coordinated action of Bcl-xL phosphorylation and p53 translocation to the mitochondria resulted in conformational activation of Bak oligomerization, facilitating cytochrome c release and apoptosis induction. In addition, the combinatorial treatment with mitomycin C and bortezomib significantly inhibited intraperitoneal tumor growth in LS174T cells and increased apoptosis, especially under hypoxic conditions in vivo. This study provides a preclinical rationale for the use of combination therapies for CPC patients. Implications: The combination of a chemotherapy agent and proteasome inhibitor at sublethal doses induced synergistic apoptosis, in particular under hypoxia, in vitro and in vivo through coordinated action of Bcl-xL and p53 on Bak activation.
UR - http://www.scopus.com/inward/record.url?scp=84950326367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950326367&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-15-0237
DO - 10.1158/1541-7786.MCR-15-0237
M3 - Article
C2 - 26354682
AN - SCOPUS:84950326367
SN - 1541-7786
VL - 13
SP - 1533
EP - 1543
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 12
ER -